Want to see ENVB full AI Analyst Report?
Enveric Biosciences (ENVB) Stock Statistics & Valuation Metrics
Total Valuation
Enveric Biosciences has a market cap or net worth of $6.40M. The enterprise value is -$2.79M.
- Market Cap
- $6.40M
- Enterprise Value
- -$2.79M
Share Statistics
Enveric Biosciences has 4,475,884 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,475,884
- Owned by Insiders
- 13.67%
- Owned by Institutions
- 8.03%
Financial Efficiency
Enveric Biosciences’s return on equity (ROE) is -2.90 and return on invested capital (ROIC) is -210.04%.
- Return on Equity (ROE)
- -2.90
- Return on Assets (ROA)
- -2.38
- Return on Invested Capital (ROIC)
- -210.04%
- Return on Capital Employed (ROCE)
- -2.10
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.02M
- Employee Count
- 6
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Enveric Biosciences is -0.09. Enveric Biosciences’s PEG ratio is -0.00.
- PE Ratio
- -0.09
- PS Ratio
- 0.00
- PB Ratio
- 0.71
- Price to FCF
- -0.75
- Price to Operating Cash Flow
- -0.67
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Enveric Biosciences had revenue of 0 and earned -12.13M in profits. Earnings per share was -36.24.
- Revenue
- 0
- Gross Profit
- -200.86K
- Operating Income
- -8.77M
- Pretax Income
- -8.77M
- Net Income
- -12.13M
- EBITDA
- -8.57M
- Earnings Per Share (EPS)
- -36.24
Cash Flow
In the last 12 months, operating cash flow was -8.56M and capital expenditures -4, giving a free cash flow of -8.56M billion.
- Operating Cash Flow
- -8.56M
- Free Cash Flow
- -8.56M
- Free Cash Flow per Share
- -2.15
Dividends & Yields
Enveric Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -133.76%
- Earnings Yield
- -153.10%
Stock Price Statistics
- Beta
- 1.00
- 52-Week Price Change
- -76.67%
- 50-Day Moving Average
- 1.45
- 200-Day Moving Average
- 1.99
- Relative Strength Index (RSI)
- 48.18
- Average Volume (3m)
- 85.46K
Important Dates
Enveric Biosciences upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Enveric Biosciences as a current ratio of 5.38, with Debt / Equity ratio of 0.00%
- Current Ratio
- 5.38
- Quick Ratio
- 5.38
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.55
- Interest Coverage Ratio
- -82777.81
Taxes
In the past 12 months, Enveric Biosciences has paid 3.36M in taxes.
- Income Tax
- 3.36M
- Effective Tax Rate
- -0.38
Enterprise Valuation
Enveric Biosciences EV to EBITDA ratio is 0.22, with an EV/FCF ratio of 0.22.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.22
- EV to Free Cash Flow
- 0.22
- EV to Operating Cash Flow
- 0.22
Balance Sheet
Enveric Biosciences has $8.30M in cash and marketable securities with $0.00 in debt, giving a net cash position of $8.30M billion.
- Cash & Marketable Securities
- $8.30M
- Total Debt
- $0.00
- Net Cash
- $8.30M
- Net Cash Per Share
- $1.85
- Tangible Book Value Per Share
- $2.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Enveric Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 87.05%
Scores
- Smart Score
- ―
- AI Score
- 44